Literature DB >> 1860689

Prevention of portal hypertension and portosystemic shunts by early chronic administration of clonidine in conscious portal vein-stenosed rats.

H C Lin1, O Soubrane, D Lebrec.   

Abstract

The hemodynamic effects, including mesenteric-systemic shunts of early chronic administration of clonidine, were studied in conscious, unrestrained, portal vein-stenosed rats. In rats receiving early chronic clonidine (600 micrograms.kg-1.day-1 by gavage), begun 3 days before portal vein stenosis and then administered continuously for 10 consecutive days, portal pressure (10.0 +/- 1.5 mm Hg) and degree of mesenteric-systemic shunts (58% +/- 25%) were significantly lower than in the placebo group (15.2 +/- 1.5 mm Hg and 83% +/- 7%, respectively). The effects were observed either 2 to 3 hr or 18 to 24 hr after the last dose of clonidine. In rats receiving clonidine continuously for 5 days, starting 5 days after portal vein stenosis, portal pressure (11.0 +/- 1.3 mm Hg) was significantly lower than in the placebo group, but mesenteric-systemic shunts (82% +/- 8%) were not significantly different. In rats receiving a single oral dose of clonidine (600 micrograms/kg) 10 days after portal vein stenosis, portal pressure (11.8 +/- 2.1 mm Hg), measured 2 to 3 hr after clonidine administration, was significantly lower than in the placebo group. Mesenteric-systemic shunts (83% +/- 8%), however, were not significantly different from the placebo group. In addition, 18 to 24 hr after a single dose of clonidine, hemodynamic values returned to basal conditions. We also demonstrated that chronic clonidine administration begun before portal vein stenosis can reduce the initial increase in portal pressure after this procedure. We concluded that early chronic clonidine administration reduces the severity of portal hypertension and the development of portosystemic shunts in portal vein-stenosed rats.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1860689

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  6 in total

1.  Hemodynamic effects of the early and long-term administration of propranolol in rats with intrahepatic portal hypertension.

Authors:  Lionel Fizanne; Nicolas Régenet; Jianhua Wang; Frédéric Oberti; Frédéric Moal; Jerôme Roux; Yves Gallois; Sophie Michalak; Paul Calès
Journal:  Hepatol Int       Date:  2008-04-12       Impact factor: 6.047

2.  Hemodynamic effects of eight-day octreotide and propranolol administration in portal hypertensive rats.

Authors:  Y T Huang; Y R Cheng; H C Lin; M C Hou; S D Lee; C Y Hong
Journal:  Dig Dis Sci       Date:  1998-02       Impact factor: 3.199

3.  Bacterial translocation to mesenteric lymph nodes increases in chronic portal hypertensive rats.

Authors:  Miguel-Angel Llamas; María-Angeles Aller; Domingo Marquina; María-Paz Nava; Jaime Arias
Journal:  Dig Dis Sci       Date:  2009-10-16       Impact factor: 3.199

4.  Effect of early propranolol administration on portal hypertensive gastropathy in cirrhotic rats.

Authors:  Savas Rafailidis; Charalampos Demertzidis; Konstantinos Ballas; Michail Alatsakis; Nikolaos Symeonidis; Theodoros Pavlidis; Kyriakos Psarras; Valentini Tzioufa-Asimakopoulou; Athanassios Sakadamis
Journal:  World J Gastroenterol       Date:  2009-09-14       Impact factor: 5.742

5.  Effect of early bosentan administration on the development of esophageal varices in cirrhotic rats: experimental study in Wistar rats.

Authors:  Savas Rafailidis; Konstantinos Ballas; Kyriakos Psarras; Theodoros Pavlidis; Eleni Emoniotou; Rodoula Papamichali; Georges Kalodimos; Georges Marakis; Athanassios Sakadamis; Georges Koukoulis
Journal:  J Gastroenterol       Date:  2008-11-18       Impact factor: 7.527

6.  Budesonide ameliorates early portal hypertension in the rat: possible antiexudative splanchnic action.

Authors:  M Vega De Céniga; F Valdés; M A Aller; M P Nava; T Chivato; J Arias
Journal:  Inflammopharmacology       Date:  2003       Impact factor: 4.473

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.